Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients

被引:758
作者
Kalantar-Zadeh, K.
Kuwae, N.
Regidor, D. L.
Kovesdy, C. P.
Kilpatrick, R. D.
Shinaberger, C. S.
McAllister, C. J.
Budoff, M. J.
Salusky, I. B.
Kopple, J. D.
机构
[1] Harbor UCLA Med Ctr, Div Nephrol & Hypertens, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA
[3] Nakagami Hosp, Dept Nephrol, Okinawa, Japan
[4] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA
[5] Salem Vet Affairs Med Ctr, Div Nephrol, Salem, VA USA
[6] DaVita Inc, El Segundo, CA USA
[7] Harbor UCLA Med Ctr, Div Cardiol, Torrance, CA 90502 USA
[8] Univ Calif Los Angeles, Ctr Hlth Sci, Div Pediat Nephrol, Los Angeles, CA 90024 USA
关键词
renal osteodystrophy; paricalcitol; cardiovascular death; time-dependent Cox model; malnutrition-inflammation-cachexia syndrome; STAGE RENAL-DISEASE; PARATHYROID-HORMONE; MINERAL METABOLISM; VITAMIN-D; DIALYSIS OUTCOMES; MORTALITY RISK; ASSOCIATION; CALCIUM; ERYTHROPOIETIN; CALCIFICATION;
D O I
10.1038/sj.ki.5001514
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Although renal osteodystrophy and vitamin D analogs may be related to survival in maintenance hemodialysis (MHD) patients, most studies have examined associations between baseline values and survival without accounting for variations in clinical and laboratory measures over time. We examined associations between survival and quarterly laboratory values and administered paricalcitol in a 2-year ( July 2001-June 2003) cohort of 58 058 MHD patients from all DaVita dialysis clinics in USA using both time-dependent Cox models with repeated measures and fixed-covariate Cox models with only baseline values. Whereas hypercalcemia and hyperphosphatemia were robust predictors of higher death risk in all models, the association between serum calcium and mortality was different in time-varying models. Changes in baseline calcium and phosphorus values beyond the Kidney Disease Outcome Quality Initiative recommended targets were associated with increased mortality. Associations between high serum parathyroid hormone and increased death risk were masked by case-mix characteristics of MHD patients. Time-varying serum alkaline phosphatase had an incremental association with mortality. Administration of any dose of paricalcitol was associated with improved survival in time-varying models. Controlling for nutritional markers may introduce overadjustment bias owing to their strong collinearity with osteodystrophy surrogates. Whereas both time-dependent and fixed-covariate Cox models result in similar associations between osteodystrophy indicators and survival, subtle but potentially clinically relevant differences between the two models exist, probably because fixed models do not account for variations of osteodystrophy indices and changes in medication dose over time.
引用
收藏
页码:771 / 780
页数:10
相关论文
共 45 条
  • [1] Vitamin D treatment in chronic kidney disease
    Andress, DL
    [J]. SEMINARS IN DIALYSIS, 2005, 18 (04) : 315 - 321
  • [2] Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation
    Avram, MM
    Mittman, N
    Myint, MM
    Fein, P
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (06) : 1351 - 1357
  • [3] High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients
    Barany, P
    Divino, JC
    Bergstrom, J
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 29 (04) : 565 - 568
  • [4] Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis
    Block, GA
    Martin, KJ
    de Francisco, ALM
    Turner, SA
    Avram, MM
    Suranyi, MG
    Hercz, G
    Cunningham, J
    Abu-Alfa, AK
    Messa, P
    Coyne, DW
    Locatelli, F
    Cohen, RM
    Evenepoel, P
    Moe, SM
    Fournier, A
    Braun, J
    McCary, LC
    Zani, VJ
    Olson, KA
    Drüeke, TB
    Goodman, WG
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) : 1516 - 1525
  • [5] Mineral metabolism, mortality, and morbidity in maintenance hemodialysis
    Block, GA
    Klassen, PS
    Lazarus, JM
    Ofsthun, N
    Lowrie, EG
    Chertow, GM
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (08): : 2208 - 2218
  • [6] Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study
    Block, GA
    Hulbert-Shearon, TE
    Levin, NW
    Port, FK
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) : 607 - 617
  • [7] Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients
    Chertow, GM
    Burke, SK
    Raggi, P
    [J]. KIDNEY INTERNATIONAL, 2002, 62 (01) : 245 - 252
  • [8] Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients
    Cotter, DJ
    Stefanik, K
    Zhang, Y
    Thamer, M
    Scharfstein, D
    Kaufman, J
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (10) : 1086 - 1095
  • [9] Differential effects of acute administration of 19-nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients
    Coyne, DW
    Grieff, M
    Ahya, SN
    Giles, K
    Norwood, K
    Slatopolsky, E
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 40 (06) : 1283 - 1288
  • [10] DAUGIRDAS JT, 1989, INT J ARTIF ORGANS, V12, P420